×
About 293 results

ALLMedicine™ Factor VII Deficiency Center

Research & Reviews  104 results

Phenotypic and genotypic characterization of two factor VII deficiency patients from so...
https://doi.org/10.1097/MBC.0000000000001145
Blood Coagulation & Fibrinolysis : an International Journ... Wang A, Su D et. al.

Jul 23rd, 2022 - The congenital factor VII deficiency (FVIID) is a rare autosomal recessive haemorrhagic disease caused by mutations in the F7 gene. The aim of this study was to identify the mutations causing FVII deficiency and explain the genotype-phenotype asso...

Clinical phenotype and F7 gene genotype in 40 Tunisian patients with congenital factor ...
https://doi.org/10.1097/MBC.0000000000001139
Blood Coagulation & Fibrinolysis : an International Journ... Ouardani C, Elmahmoudi H et. al.

Jul 9th, 2022 - Congenital factor VII (FVII) deficiency is an autosomal recessive bleeding disorder characterized by a weak phenotypic and genotypic correlation. This study aimed to determine the genetic alterations of 40 Tunisian patients and to evaluate their r...

Novel heterozygous F7 gene mutation (c. C1286T) associated with congenital factor VII d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102670
Journal of Clinical Laboratory Analysis; Tang H, Luan X et. al.

Mar 30th, 2022 - Congenital factor VII (FVII) deficiency is a rare inherited autosomal recessive disorder characterized by prolongation of prothrombin time and low FVII coagulation activity, which may increase the risk of bleeding. A 66-year-old man with acute pos...

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
https://clinicaltrials.gov/ct2/show/NCT03372993

Feb 15th, 2022 - This is a Non-interventional, observational, prospective evaluation of immunogenicity (neutralizing antibodies toward FVII) of patients with Hemophilia A or B with inhibitors, Factor VII Deficiency, Glanzmann's thrombasthenia, who have received on...

A novel compound heterozygous variant linked to hematuria in a family with hereditary f...
https://doi.org/10.1002/jgm.3398
The Journal of Gene Medicine; Hu YN, Gan YM et. al.

Nov 18th, 2021 - Hereditary factor VII deficiency (FVIID) is a rare congenital autosomal recessive bleeding disorder. In clinical manifestations, its onset is caused by variant of the F7 gene (NM_019616) with strong heterogeneity. We identified a family with hemat...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  7 results

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
https://clinicaltrials.gov/ct2/show/NCT03372993

Feb 15th, 2022 - This is a Non-interventional, observational, prospective evaluation of immunogenicity (neutralizing antibodies toward FVII) of patients with Hemophilia A or B with inhibitors, Factor VII Deficiency, Glanzmann's thrombasthenia, who have received on...

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
https://clinicaltrials.gov/ct2/show/NCT03079063

Feb 4th, 2021 - The purpose of this multicentre, randomized, double blinded, single dose, two-way cross-over study, is to compare the pharmacokinetics (PK) of biosimilar eptacog alfa (activated) with Novoseven in 24 patients, adult and children (>12 years), not b...

Correlation Between PT and INR to Factor 7
https://clinicaltrials.gov/ct2/show/NCT03788460

Dec 27th, 2018 - Factor VII is one of the main components of the coagulation process. It belongs to the serine proteases and it dependents on vitamin K in order to function. Its primary function is to initiate the clotting process itself, along with tissue factor:...

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency
https://clinicaltrials.gov/ct2/show/NCT02470871

Apr 26th, 2017 - The purpose of this study is to investigate the pharmacokinetics (PK) and safety of rVIIa-FP (CSL689) in a total of 10 to 16 male or female adults with inherited coagulation factor VII (FVII) deficiency. Subjects will receive a single dose of thei...

Treatment of Congenital Factor VII Deficiency
https://clinicaltrials.gov/ct2/show/NCT01779921

Jan 12th, 2017 - This study is conducted globally. The aim of this study is to describe the treatment modalities and outcomes of bleeding episodes, surgery and prophylaxis in patients with factor VII (FVII) deficiency in addition to evaluate the presence (in alrea...

see more →

News  4 results

Bleeding disorders don’t carry increased risks for patients undergoing endoscopy
https://www.mdedge.com/hematology-oncology/article/196316/bleeding-disorders/bleeding-disorders-dont-carry-increased-risks
Andrew D. Bowser

Mar 13th, 2019 - When managed by an experienced team, patients with inherited bleeding disorders undergoing gastrointestinal endoscopy are not at increased bleeding risk, according to researchers reporting the largest series of such patients to date. The postendos.

Extended half-life clotting factors are safe, effective, and pricey
https://www.mdedge.com/familymedicine/article/115069/bleeding-disorders/extended-half-life-clotting-factors-are-safe
Hematology News; Neil Osterweil

Oct 5th, 2016 - ORLANDO – Early experience with extended half-life clotting factor concentrates suggests these products are generally safe and effective, at least in the short term, according to hemophilia experts. “In adolescent and adult patients, the extended.

Extended half-life clotting factors are safe, effective, and pricey
https://www.mdedge.com/internalmedicine/article/115069/bleeding-disorders/extended-half-life-clotting-factors-are-safe
Neil Osterweil

Oct 5th, 2016 - ORLANDO – Early experience with extended half-life clotting factor concentrates suggests these products are generally safe and effective, at least in the short term, according to hemophilia experts. “In adolescent and adult patients, the extended.

Off-Label Use of Hemophilia Drug May Be Risky
https://www.medpagetoday.com/cardiology/strokes/2509

Jan 18th, 2006 - Action Points Carefully weigh the potential risk of thromboembolic events suggested by this study when considering prescribing NovoSeven for an off-label indication to non-hemophiliacs. ROCKVILLE, Md., Jan. 18 - Off-label use of the hemophilia dru...

see more →